logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Somatostatin Analog class drugs

    FiltersReset Filters
    5 results

    • octreotide acetate

      (octreotide acetate)
      Hainan Shuangcheng Pharmaceuticals Co., Ltd.
      Usage: Octreotide acetate injection is indicated for reducing growth hormone and IGF-1 levels in acromegaly, treating severe diarrhea and flushing from metastatic carcinoid tumors, and managing profuse watery diarrhea from vasoactive intestinal peptide tumors (VIPomas). Clinical trials did not demonstrate improvements in tumor size or growth rate.

    • sandostatin lar depot

      (octreotide acetate)
      Novartis Pharmaceuticals Corporation
      Usage: SANDOSTATIN LAR DEPOT is indicated for long-term maintenance therapy in acromegaly, and to treat severe diarrhea associated with metastatic carcinoid tumors and VIP-secreting tumors (VIPomas) in patients who have tolerated initial treatment with Sandostatin Injection.

    • signifor

      (pasireotide)
      Recordati Rare Diseases, Inc.
      Usage: SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease who are not candidates for pituitary surgery or in cases where surgery has not been curative.

    • signifor lar

      (pasireotide)
      Recordati Rare Diseases, Inc.
      Usage: SIGNIFOR LAR is indicated for treating acromegaly in patients with inadequate surgical response or unsuitable for surgery, and for Cushing's disease when pituitary surgery is not an option or hasn't been curative.

    • somatuline depot

      (lanreotide acetate)
      Ipsen Biopharmaceuticals, Inc.
      Usage: SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.